title: Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas.
abstract: Glioblastomas are the most common primary brain tumors in adults. These tumors exhibit a high degree of vascularization, and malignant progression from astrocytoma to glioblastoma is often accompanied by increased angiogenesis and the upregulation of vascular endothelial growth factor and its receptors. In this study, we investigated the in vivo antiangiogenic and antitumor effects of brain-specific angiogenesis inhibitor 1 (BAI1) using human glioblastoma cell lines. Glioblastoma cells were transduced with an adenoviral vector encoding BAI1 (AdBAI1), and Northern and Western blot analyses, respectively, demonstrated BAI1 mRNA and protein expression in the transduced tumor cells. Using an in vivo neovascularization assay, we found that angiogenesis surrounding AdBAI1-transduced glioblastoma cells transplanted into transparent skinfold chambers of SCID mice was significantly impaired compared to control treated cells. Additionally, in vivo inoculation with AdBAI1 of established subcutaneous or intracerebral transplanted tumors significantly impaired tumor growth and promoted increased mouse survival. Morphologically, the tumors exhibited signs of impaired angiogenesis, such as extensive necrosis and reduced intratumoral vascular density. Taken together, these data strongly indicate that BAI1 may be an excellent gene therapy candidate for the treatment of brain tumors, especially human glioblastomas.
authors.affiliation: Division of Molecular Therapy, Advanced Clinical Research Center, The University of Tokyo, Tokyo, Japan.
authors.forename: X
authors.initials: X
authors.lastname: Kang
authors.forename: X
authors.initials: X
authors.lastname: Xiao
authors.forename: M
authors.initials: M
authors.lastname: Harata
authors.forename: Y
authors.initials: Y
authors.lastname: Bai
authors.forename: Y
authors.initials: Y
authors.lastname: Nakazaki
authors.forename: Y
authors.initials: Y
authors.lastname: Soda
authors.forename: R
authors.initials: R
authors.lastname: Kurita
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: F
authors.initials: F
authors.lastname: Komine
authors.forename: K
authors.initials: K
authors.lastname: Izawa
authors.forename: R
authors.initials: R
authors.lastname: Kunisaki
authors.forename: M
authors.initials: M
authors.lastname: Setoyama
authors.forename: H
authors.initials: H
authors.lastname: Nishimori
authors.forename: A
authors.initials: A
authors.lastname: Natsume
authors.forename: M
authors.initials: M
authors.lastname: Sunamura
authors.forename: L
authors.initials: L
authors.lastname: Lozonshi
authors.forename: I
authors.initials: I
authors.lastname: Saitoh
authors.forename: T
authors.initials: T
authors.lastname: Tokino
authors.forename: S
authors.initials: S
authors.lastname: Asano
authors.forename: Y
authors.initials: Y
authors.lastname: Nakamura
authors.forename: K
authors.initials: K
authors.lastname: Tani
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D042501:Angiogenic Proteins / Q000096:biosynthesis* / Q000235:genetics; D000818:Animals; D001932:Brain Neoplasms / Q000098:blood supply* / Q000473:pathology / Q000628:therapy; D045744:Cell Line, Tumor; D015316:Genetic Therapy; D005822:Genetic Vectors; D005909:Glioblastoma / Q000098:blood supply* / Q000473:pathology / Q000628:therapy; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000628:therapy*; D012333:RNA, Messenger / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled; D014161:Transduction, Genetic
chemical_list: C468226:ADGRB1 protein, human; D042501:Angiogenic Proteins; D012333:RNA, Messenger; D043562:Receptors, G-Protein-Coupled